Late Effects of Estrogen Deprivation in Breast Cancer

Video

This video examines the late effects of estrogen deprivation in both younger and older breast cancer patients, including bone thinning, heart disease, and dementia.

Treatment with aromatase inhibitors exposes patients to late effects, including the risk of bone thinning, heart disease, and dementia.

In this video Ann Partridge, MD, MPH, of the Dana-Farber Cancer Institute in Boston, discusses how to monitor for and manage these late effects of estrogen deprivation in both younger and older breast cancer patients.

Recent Videos
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
2 KOLs are featured in this series.
Related Content
Laser vision correction. A patient and team of surgeons in the operating room during ophthalmic surgery. Eyelid speculum. Lasik treatment.| Image Credit: © romaset-stock.adobe.com

Brachytherapy/Vitrectomy, Silicone Oil Confer Positive Uveal Melanoma DMFS

Ariana Pelosci
September 28th 2025
Article

An 80% disease metastasis-free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

The Lived Experience of Talquetamab Therapy in a Patient With Multiple Myeloma

ONCOLOGY Staff
September 27th 2025
Article

Karen Kehl shares her decade-long journey with multiple myeloma, discussing treatment options and the impact of bispecific antibodies like talquetamab with Binod Dhakal, MD.

How to Discuss Death: A Conversation of Mortality in Cancer Care

How to Discuss Death: A Conversation of Mortality in Cancer Care

Daniel C. McFarland, DO;William Breitbart, MD
September 22nd 2025
Podcast

Daniel C. McFarland, DO; and guest William S. Breitbart, MD, discuss the critical role of meaning-centered therapy in addressing the psychosocial needs of patients with cancer.

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Ziftomenib Shows Significant Benefit in Relapsed/Refractory NPM1+ AML

Russ Conroy
September 26th 2025
Article

Data from KOMET-001 support ziftomenib as a new potential option for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

Following over a decade of oversight, no cases of Torsades de pointes or unexplained sudden deaths were reported among US patients who received vandetanib in REMS assessments.

FDA Drops REMS Requirement for Vandetanib in Medullary Thyroid Cancer

Tim Cortese
September 26th 2025
Article

Physicians are no longer required to have special certification to administer vandetanib to patients with medullary thyroid cancer.